Autres langues Theratechnologies Inc.

Actions

TH

CA88338H7040

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:59 26/06/2024			Varia. 5j.	Varia. 1 janv.
2,14 ^CAD	+20,22 %		+18,23 %	0,00 %

09/05	Theratechnologies inc. annonce la nomination de Frank Holler à titre de président du conseil d'administration	CI
09/05	Transcript : Theratechnologies Inc. - Shareholder/Analyst Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update	26/06
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	23/05
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	23/05
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors	23/05
Theratechnologies Reports on its Annual Meeting of Shareholders	09/05
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors	09/05
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting	02/05
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	15/04
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	11/04
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	10/04
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	10/04
Theratechnologies: Fiscal Q1 Earnings Snapshot	10/04
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	10/04
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	10/04
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	10/04
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	10/04
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	10/04
North American Morning Briefing : Traders Await -2-	10/04
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	08/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Theratechnologies Inc.

Actions

TH

CA88338H7040

Autres langues

Filtres